AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01335139 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Description: Participants randomized to receive sublingual allergen tablet immunotherapy with placebo injections.
Study NCT01335139 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy (SCIT)
Description: Participants randomized to receive subcutaneous injection immunotherapy with placebo tablets. Subcutaneous immunotherapy was included as a positive control.
Study NCT01335139 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to double-placebo tablets and injections. This group was included as a negative control.
Study NCT01335139 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants randomized to double-placebo tablets and injections. This group was included as a negative control.
Study NCT01645072 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low glycemic index diet
Description: Diet modification in addition to ongoing anti epileptic drug treatment. Medium and high-GI carbohydrates (GI >55) will be eliminated from the diet and only food items with low glycemic index (GI \<55) will be allowed. Parent will be given a list of low glycemic index food items. They will also be given a list of food items (medium and high glycemic index) which should be avoided.
Study NCT01645072 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: The ongoing anti epileptic drug treatment will be continued without change.
Study NCT02414308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adipose tissue stem cell injection
Description: Stem cell will be harvested through adipose tissue by liposuction and isolation occurred Injection will distribute through corpora cavernosa and dorsal penile artery
Study NCT01933308 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous high intensity training-CT80
Description: Continuous exercise training at 80% of peak work rate Heart rate (HR) response observed at their target training intensity will be identified from an incremental exercise test completed at baseline. Subjects will be asked to train within ±5beats/min of this HR. Subjects will also perform upper-extremity strength training, stretching and relaxation exercises. Overall, sessions will last approximately 2hrs, including cycling (45-60min), strength training (30min), stretching (10min) and relaxation exercises (20min). Sessions will be held on Mondays, Wednesdays and Fridays. Supervision will be provided by clinical exercise physiologists trained by Dr. Pepin. Self-management training (Living Well with COPD®) will be provided by a healthcare practitioner trained by Dr. Lavoie.
Study NCT01933308 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training at ventilatory threshold-CTVT
Description: Continuous exercise training at the ventilatory threshold Heart rate (HR) response observed at their target training intensity will be identified from an incremental exercise test completed at baseline. Subjects will be asked to train within ±5beats/min of this HR. Subjects will also perform upper-extremity strength training, stretching and relaxation exercises. Overall, sessions will last approximately 2hrs, including cycling (45-60min), strength training (30min), stretching (10min) and relaxation exercises (20min). Sessions will be held on Mondays, Wednesdays and Fridays. Supervision will be provided by clinical exercise physiologists trained by Dr. Pepin. Self-management training (Living Well with COPD®) will be provided by a healthcare practitioner trained by Dr. Lavoie.
Study NCT01933308 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interval training-IT
Description: High intensity interval training Heart rate (HR) response observed at their target training intensity will be identified from an incremental exercise test completed at baseline. Subjects will be asked to train within ±5beats/min of this HR. Subjects will also perform upper-extremity strength training, stretching and relaxation exercises. Overall, sessions will last approximately 2hrs, including cycling (45-60min), strength training (30min), stretching (10min) and relaxation exercises (20min). Sessions will be held on Mondays, Wednesdays and Fridays. Supervision will be provided by clinical exercise physiologists trained by Dr. Pepin. Self-management training (Living Well with COPD®) will be provided by a healthcare practitioner trained by Dr. Lavoie.
Study NCT05398237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Solar Simulated Light (SSL)
Description: Acute SSL will be delivered to sun damaged skin at a rate of two-times the minimal erythema dose of each individual subject. Minimal erythema dose is defined as the smallest dose of energy necessary to produce confluent erythema with four distinct borders at 22-26 hours post-exposure.
Study NCT02091817 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oxytocin
Description: Intervention will be examined on control group, and on experimental group as well.
Study NCT02091817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Intervention will be examined on control group, and on experimental group as well.
Study NCT02091817 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo will be given to control group and experimental group as well.
Study NCT02091817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be given to control group and experimental group as well.
Study NCT00876616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus+Mycophenolate mofetil
Description: FK506 4mg/d,MMF 1.0g/d
Study NCT00876616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: CTX 0.75g/m2 BSA
Study NCT01521130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Medication doses are defined on a mg/kg basis. Dosage form, frequency and titration schedule is based on accepted clinical practice.
Study NCT01650558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care prophylaxis
Description: Daily trimethoprim sulfamethoxazole
Study NCT01650558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ) prophylaxis
Description: Discontinue standard of care and start weekly CQ.
Study NCT01557426 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ultrasound
Description: A linear ultrasound transducer will be used with ultrasound gel to obtain an image of subcutaneous structures and tissues over the involved body site. Ultrasound video will be recorded whenever possible, however studies that are not recorded will still be included. Video recording will be initiated once the desired image is obtained. Appropriate measurements will be made and views identified using the features of the ultrasound machine. Scanning of the contralateral body segment will then be performed. The ultrasound probe will be thoroughly cleaned and disinfected between ultrasound scans.
Study NCT02572323 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tesamorelin
Description: Tesamorelin is an injectable medication already approved by the U.S. FDA to treat abdominal fat accumulation in HIV
Study NCT02938026 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Study NCT02938026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Intensive Lifestyle Counselling
Study NCT01959997 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Redo PVI
Study NCT01959997 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI + RDN
Study NCT02468180 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon-occluded retrograde transvenous obliteration
Description: Balloon-occluded retrograde transvenous obliteration
Study NCT02468180 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic cyanoacrylate injection
Description: Endoscopic cyanoacrylate injection
Study NCT02468180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-butyl-2-cyanoacrylate
Study NCT02468180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lauromacrogol
Study NCT01160289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2452473
Description: Administered orally, once daily for 12 weeks
Study NCT01160289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tadalafil
Description: Administered orally, once daily for 12 weeks
Study NCT01160289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: Administered orally, once daily for 12 weeks
Study NCT02572323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tesamorelin
Description: Tesamorelin is an injectable medication already approved by the U.S. FDA to treat abdominal fat accumulation in HIV
Study NCT01160289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo (tadalafil)
Description: Administered orally, once daily for 12 weeks
Study NCT01160289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo (tadalafil)
Description: Administered orally, once daily for 12 weeks
Study NCT03395483 — intervention group
Intervention type: OTHER
Intervention: Haemodynamic monitoring
Description: see Group description
Study NCT01096836 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: macronutrient and energy manipulation
Study NCT02828735 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: respiration assessment
Description: Respiration Breathing Exercise
Study NCT04506541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kangaroo Care
Description: Kangaroo care application started in the first minute after giving birth in mothers who were in the kangaroo care group and came to the delivery room.
Study NCT03827135 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physical therapy
Description: Cervical isometrics 10 repetitions×1 set, 4 days/week and targeted muscle strechings (trapezius, scalenes and sternocleidomastoid) 10 repetitions×1 set, 4 days/week.~Total of 4 sessions were given each consisting of 40 mins.
Study NCT03827135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cyriax manipulation
Description: Experimental group was given cyriax manipulation protocol along with the cervical isometrics and muscle strechings.~Traction with rotation was not given in cases of bilateral arm pain. cervical isometrics 10 repetitions×1 set, 4 days/week and targeted muscle strechings (trapezius, scalenes and sternocleidomastoid) 10 repetitions×1 set, 4 days/week.~Total of 4 sessions were given each consisting of 40 mins.
Study NCT03982641 — intervention group
Intervention type: PROCEDURE
Intervention: all colorectal cancer surgical procedures
Description: colorectal cancer surgical procedures
Study NCT00115505 — intervention group
Intervention type: OTHER
Intervention: quality-of-life assessment
Description: Complete Subjective Significance Questionnaire, MOS Social Support Survey, Patient Preferences, CALGB Background Information, and EQ-5D and QOL Assessment Form, EORTC QLQ-C30 and EORTC QLQ-BR23
Study NCT00115505 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete the Employment and Informal Care Cost Assessment and Peripheral Neuropathy Assessments
Study NCT01944007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cross-Linked Polyelectrolyte (CLP)
Description: CLP was administered orally, in capsules, for 9 consecutive days.
Study NCT01160289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo (LY2452473)
Description: Administered orally, once daily for 12 weeks
Study NCT01001338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA594
Description: Uricosuric agent for the treatment of gout.
Study NCT02111447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol infusion with nasal oxygen
Study NCT02111447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol infusion with an LMA
Study NCT02111447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane with an LMA
Study NCT02111447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoflurane
Description: Isoflurane with an LMA
Study NCT01054105 — intervention group
Intervention type: DRUG
Intervention: Iloprost
Description: Iloprost inhalation, 2.5 - 5mcg, 6 times per day
Study NCT02161796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FG-4592
Description: Oral
Study NCT02161796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral
Study NCT01001338 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study NCT01001338 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Allopurinol
Description: Allopurinol
Study NCT05052034 — intervention group
Intervention type: OTHER
Intervention: Music
Description: Through headphones, the patients would listen to different types of music during the intervention.
Study NCT01001338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Allopurinol
Study NCT01940068 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Amino acid based formula
Study NCT01940068 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino acid based formula
Study NCT01237275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRI treated group
Description: characterize in arm of a study (SSRI treated group)
Study NCT00903006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Starting dose of 500 mg through a needle into muscle on Days 1 and 15 of Cycle 1 and on Day 1 of Cycles 2 and beyond. On Day 1 of Cycle 1, injections into 2 different muscles, all other times one injection.
Study NCT00903006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MK-0646
Description: Group 3 or Group 4, receive starting dose of 5 mg/kg by vein on Days 1, 18, 15, and 22 of every cycle.
Study NCT00903006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib
Description: Group 2 or Group 4, starting dose of 70 mg (capsules) by mouth daily.
Study NCT03287921 — intervention group
Intervention type: DRUG
Intervention: mono bronchodilatation
Description: within indication according to current GOLD recommendation
Study NCT03287921 — intervention group
Intervention type: DRUG
Intervention: dual bronchodilatation
Description: within indication according to current GOLD recommendation
Study NCT00857285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil
Description: olmesartan medoxomil oral tablets, once daily for up to 12 weeks
Study NCT00857285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: losartan potassium
Description: losartan oral tablets, once daily for up to 12 weeks
Study NCT02890212 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: selenium supplementation
Description: administration of selenium pills (400 micrograms) for randomized subjects
Study NCT02890212 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: administration of placebo pills for randomized subjects
Study NCT01253109 — intervention group
Intervention type: DEVICE
Intervention: SENSIMED Triggerfish
Description: Contact lens-based device for continuous IOP monitoring
Study NCT03203031 — intervention group
Intervention type: PROCEDURE
Intervention: General anesthesia
Description: Standard general anesthesia
Study NCT03572179 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3d printed positioning tray
Description: 3d printed positioning tray for lingual fixed retainer placement in treatment group
Study NCT00644358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vilazodone
Description: titration to 40 milligrams (mg) every day (qd) for 1 year
Study NCT03180385 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurally-Adusted Ventilatory Assist (NAVA)
Description: Delivery of positive pressure is based on the electrical activity of the diaphragm (Edi) via a nasogastric (NG) catheter that is placed on the phrenic nerve, which runs along the esophagus. This results in synchronous ventilation for the patient.
Study NCT03180385 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biphasic Positive Airway Pressure Support (BiPAP)
Description: Conventional form of non-invasive respiratory support that does not deliver positive airway pressure in a synchronous fashion.
Study NCT01774201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing exercises
Description: Breathing exercises with positive expiratory pressure.
Study NCT01406301 — intervention group
Intervention type: DRUG
Intervention: fondaparinux
Description: fondaparinux
Study NCT03203031 — intervention group
Intervention type: PROCEDURE
Intervention: Quadratus lumborum block
Description: Guided by ultrasonography, injection of 0.5 ml/kg of ropivacaine (2 mg/ml) between the quadratus lumborum muscle and the internal oblique muscle, before skin incision
Study NCT00666601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-700 (active moiety)
Description: A TR-700 solution will be locally administered via a microdialysis probe into the skeletal muscle and subcutanous tissue (just under the skin) at a concentration of approximately 2 µg/mL at a flow rate of 1.5 µL/min for 60 minutes for a total maximum dose of 0.36 µg (0.18 µg per probe).
Study NCT00666601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 (pro-drug)
Description: Each subject enrolled in the Main study will receive a single oral dose of 600mg TR-701
Study NCT00574756 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ranolazine
Description: extended release 500 mg twice a day for two weeks
Study NCT03735836 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAG-EPA/MAG-DHA omega-3 oils
Description: The monoglyceride (MAG) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are chemically modified fish oils that fall into the Natural Health products category in Canada.
Study NCT01774032 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated), non-adjuvanted formulation
Study NCT00627588 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ProSavin
Description: ProSavin is a gene therapy designed to delivery three key enzymes involved in the synthesis of dopamine
Study NCT00627588 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: ProSavin
Description: ProSavin is a gene therapy designed to delivery three key enzymes involved in the synthesis of dopamine
Study NCT01611792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stabilization exercise protocol
Description: The stabilization exercise protocol consists of exercises focused on improving the ability of trunk muscles to stabilize the spine, beginning with training to isolate the deeper abdominal muscles as well as deep dorsal trunk muscles. Then patients were progressed to exercises that added leverage of the limbs while maintaining the co-contraction of the deeper abdominal muscles and deep dorsal trunk muscles while breathing normally. Various positions (e.g., supine and quadruped positions) were used to challenge the patients based on their tolerance. Finally, patients were progressed to exercises in more functional positions that included tasks/activities that were reported as challenging and/or painful; patients performed the tasks at the speed demanded by the particular task. Maintenance of the co-contraction of deep trunk muscles was emphasized during these functional activities.
Study NCT01611792 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength and conditioning exercise protocol
Description: This protocol contained trunk strengthening and endurance exercises. It consisted of 3 phases: 1) initial strengthening of trunk flexors/extensors in single plane movements, 2) trunk and lower-extremity stretching as well as progression of trunk-strengthening exercises to include multi-planar trunk movements. Aerobic exercises were progressed as tolerated and patient education about body biomechanics were reinforced, and 3) trunk-strengthening exercises under dynamic conditions (e.g., unstable support surface and in multi-planar trunk movements). During the 10 week protocol, exercises became more challenging, and each subject had to complete at least the first phase before moving onto the next phase in order to be included in post-testing analyses. There was no specific focus on the deep abdominal or deep dorsal trunk muscles during any of these exercises.
Study NCT01759420 — intervention group
Intervention type: DRUG
Intervention: Ondansetron
Description: 4mg of intravenous ondansetron
Study NCT02261259 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment
Description: Up to 4 sessions of osteopathic manipulative treatment (once per week)
Study NCT00735631 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SISO model-based predictive closed-loop system
Description: The single-input-single-output (SISO) model-based predictive closed-loop system will be used to guide patient-individualized ICU sedation with propofol
Study NCT02878577 — intervention group
Intervention type: DEVICE
Intervention: fMRI
Description: fMRI scans, mapping brain connectivity using EEG in combination with eye-tracking technology (Brain Network Activation (BNA) technology developed by ELMINDA), characterizing of cortical layers using magnetic resonance (the CoLI technology developed by Tel-Aviv University), and Diffusion Tensor Imaging (DTI) imaging (imaging of brain tracks).